

IAPM PERSONALISED ONCOLOGY IMPLEMENTATION MEETING

PERSONALISED ONCOLOGY ACROSS HEALTH SYSTEMS

Claudia's Journey: From Diagnosis to Measurable Access

FRIDAY
23 OCTOBER 2026

TIME
08:30–16:30

MADRID, SPAIN
Held alongside ESMO
Congress 2026 | Venue

Location: Room «A4.2» at Mezzanine Level, IFEMA

Meeting purpose: Follow Claudia's pathway from diagnosis and molecular characterisation to eligibility, access, treatment and monitoring, using different cancers and health systems to identify practical guarantees and responsibilities.

Expected outputs: Patient-pathway guarantees • Public–Private Implementation Compact • Innovation & Access Fund recommendation • IAPM Implementation Agenda

PROGRAMME:

08:30
08:50 **OPENING**
“You Have Cancer.” What Happens Next?

Three perspectives on the first effective treatment decision and what patients should expect at 24 hours, 7 days and 1 month.

- **Núria Malats, MD, PhD**, Group Leader, Genetic & Molecular Epidemiology, CNIO, Spain *(confirmed)*
- **Jose Martin Moreno**, Professor of Medicine and Public Health, University of Valencia *(confirmed)*
- **Denis Horgan, PhD**, Secretary General, IAPM *(confirmed)*

08:50
10:20 **SESSION 1**
Find It. Diagnose It. Characterise It

Early detection, pathology, NGS and liquid biopsy, and clinical utility, with health-system perspectives from Japan, Brazil and Türkiye.

Discussants:

- **Early detection:** **Núria Malats**, Group Leader, Genetic & Molecular Epidemiology, CNIO, Spain *(confirmed)*
- **Clinical utility:** **John Longshore, PhD, FACMG**, Head, Scientific Affairs, Global Oncology Diagnostics, AstraZeneca *(confirmed)*
- **State of Uptake:** **Nicola Normanno**, Director, IQN-Path; Director, Center for Advanced Molecular Diagnostics in Oncology, Policlinico Gemelli *(confirmed)*
- **Health-system perspective:** **Fábio Franke, MD**, President, Brazilian Society of Clinical Oncology (SBOC); Director, Oncosite-Oncoclinicas Clinical Research Center, Brazil

- **Patient perspective:** **Ingrid Krücken**, Vice President, Europa Donna Luxembourg (*confirmed*)
- **MRD and treatment monitoring:** **Luiz Correa**, Executive Advisor in Precision Medicine, Natera. (*confirmed*)

10:20–10:35: Coffee break

10:35

SESSION 2

11:45

Who Builds the Pathway?

Public–private responsibilities for digital pathology, liquid biopsy, MRD and national networks, with focus on ownership, evidence, financing and implementation.

- **Setting the Scene:** **Vivek Subbiah**, Associate Director, Drug Development & Precision Oncology, Stanford Cancer Institute (*confirmed*)

Discussants:

- **Digital pathology:** **Paul Hofman**, Université Côte d'Azur and Nice University Hospital (*confirmed*)
- **Lung:** **Ernest Nadal**, Head, Thoracic Tumors Section, Catalan Institute of Oncology (*Tentative*)
- **Translational Oncology:** **Dr Jesús García-Foncillas**, President of Fundación ECO (*confirmed*)
- **Precision oncology / liquid biopsy:** **Benjamin Gannon**, Vice President & General Manager, Europe and Americas, Guardant Health (*confirmed*)
- **MENA region perspective:** **Adda Bounedjar**, Head, Medical Oncology Department, CHU Blida, Algeria (*confirmed*)
- **Brain:** **Manmeet Ahkuwalia**, Chief of Medical Oncology, Deputy Director and Chief Scientific Officer, Miami Cancer Institute, Baptist Health South Florida (*confirmed*)
- **Access:** **George Kapetanakis**, President, ELLOK (*confirmed*)

11:45: 13:30: Break

13:30

SESSION 3

14:45

The Result Is Back. Can Claudia Actually Receive the Treatment?

Seven cancer pathways test whether molecular eligibility becomes timely treatment or trial access, followed by a cross-cutting discussion on a possible Innovation & Access Fund.

- **Setting the scene:** **José M. Martín-Moreno, MD, PhD**, Professor of Medicine and Public Health, University of Valencia, Spain (*confirmed*)

Discussants:

Anchor cancer pathways

- **Pancreatic cancer:** **Alfredo Carrato • Núria Malats • Ali Stunt**, Pancreatic Cancer Europe / IRYCIS • CNIO • Pancreatic Cancer Action (*confirmed*)
- **Innovator perspective:** **Lee-Anne Zinetti**, Executive Director, Global Oncology Portfolio Precision Medicine, Novartis (*confirmed*)
- **EU Perspective:** **Albrecht Stenzinger**, Vice Chair, Institute of Pathology; Professor, University Hospital Heidelberg, Germany (*confirmed*)
- **Role of Liquid Biopsy:** **Umberto Malapelle**, Associate Professor, Department of Public Health, University of Naples (*confirmed*)

Cross-cutting discussion: Does personalised oncology need an Innovation & Access Fund?

- **Lung cancer:** **Ebba Hallersjö Hult**, Head of the innovation milieu, Vision Zero Cancer, Sweden (*confirmed*)
- **Mark Schmid**, Associate Vice President, Precision Medicine, New Assets (Pipeline) and NGS Strategy, MSD
- **Breast cancer:** **Live Fagereng**, Project Manager, PRIME-ROSE; Project Lead Prevision Diagnostics, EUnetCCC (*confirmed*)

14:45–15:00: Coffee break

15:00
16:15

SESSION 4

Research Has to Reach Claudia: From European Projects to a Working Patient Pathway

Five European initiatives are tested against a single implementation question: what changes for patients, and what must happen next for that change to reach routine care?

Discussants:

- **David Suñol Moreno**, Advanced Researcher & GenAI Technical Lead, Eurecat - Technology Centre of Catalonia (**iBeChange**) (*confirmed*)
- **Ralf Hoffmann**, Principal Scientist, Philips; Industry Project Leader, **BRECISE** (*confirmed*)
- **Adrian Galiana Bordera**, Senior Biomedical & Computer Vision Engineer, IIS La Fe, Spain (**SYNTHIA**) (*confirmed*)
- **Manuel Ottaviano**, Associate Professor, Universidad Politécnica de Madrid; Project Coordinator, **SPARC** (*confirmed*)
- **Elisa Marconi**, Psychologist Psychotherapist, Clinical Psychology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy (**ON-COME**) (*confirmed*)

16.15
16:30

CLOSING

The IAPM Personalised Oncology Implementation Agenda

Patient reflection, clinical innovation, health-system implementation and next steps.

- **Clinical + innovation:** **Vivek Subbiah**, Associate Director, Drug Development & Precision Oncology, Stanford Cancer Institute (*confirmed*)
- **IAPM next steps:** **Denis Horgan**, Secretary General, IAPM (*confirmed*)

Closing commitment: Publish the Implementation Compact, define the patient-pathway guarantees and convert the day's decisions into the IAPM Personalised Oncology Implementation Agenda.

Programme and faculty are proposed and subject to final confirmation.